Form 4: SOPHIA GENETICS: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that Chief People Officer Manuela Valente sold 380 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Manuela Valente, Chief People Officer of SOPHiA GENETICS SA, sold 380 ordinary shares on May 19, 2026.
• The sale was conducted to satisfy tax withholding obligations upon the vesting of restricted stock units on May 18, 2026.
• These transactions were executed under a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $4.5985, with individual sale prices ranging from $4.54 to $4.65.
• Following the sale, Valente beneficially owns 214,691 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be a negative signal, the clear explanation of tax withholding and the use of a Rule 10b5-1 plan mitigate concerns about discretionary selling.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, which is designed to comply with insider trading regulations and provides an affirmative defense against allegations of insider trading.
• The transaction was for the purpose of covering tax withholding obligations, a common and expected event for executives upon vesting of equity awards.

Negatives

• An insider, the Chief People Officer, sold company shares, which can sometimes be perceived negatively by the market, although the reason is clearly stated as tax-related.

Risks

• While the sale is for tax purposes and under a pre-planned trading plan, any significant insider selling can create negative sentiment among investors.
• The company's stock price may be sensitive to insider transactions, even those with clear explanations.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on a completed transaction.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes under Rule 10b5-1 plans are a routine event in the biotechnology and healthcare technology sectors, particularly following significant equity award grants or vesting events. This filing is typical for executive compensation management.

Stakeholder Impact

• Shareholders: The sale is for tax purposes and executed under a pre-planned trading strategy, thus it is unlikely to have a significant negative impact on shareholder sentiment beyond the general observation of insider selling.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported transaction.

Key Dates

Keywords

SOPHIA GENETICS, SOPH, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, Beneficial Ownership